The 6th World Psoriasis and Psoriatic Arthritis Conference (WPPAC) 2021 is presented over four days in a novel virtual format and features the latest groundbreaking developments in the field of psoriasis and psoriatic arthritis research. The conference includes plenaries, lectures, oral presentation of abstracts on the latest research, presentations of challenging cases, and interactive sessions featuring Key Opinion Leaders from all over the world. The WPPAC is a unique cross-specialty forum and explores perspectives from dermatology, rheumatology, and more, all within the context of topics and priorities from people living with psoriatic disease.
With the unique challenges posed by the ongoing COVID pandemic, the 6th WPPAC 2021 is transformed for the first time into a fully virtual meeting. This new format facilitates participation from everyone in our community around the world, regardless of national travel restrictions. Prerecorded lectures and sessions remain available online after the close of the conference, and registration to access the recorded sessions is open until October. Visit https://www.ifpaworldconference.com/registration/ for instructions and information.
The theme of the 6th WPPAC 2021 is Connected, informed, and united to improve multidisciplinary care for people with psoriasis & psoriatic arthritis. The program features topics of interest to everyone active within the fields of psoriasis and psoriatic arthritis – clinicians as well as researchers. The patient perspective is centered throughout the conference, underscored by the presence and participation of patient experts and leaders.
Highlights from across the program
Wednesday, June 30; 14:00-14:45 CEST
Professor Kenji Kabashima from Japan speaks and answers questions about new pathways/drivers of immunity.
Wednesday, June 30; 15:00-15:45 CEST
Dr Rachel Summer from Germany speaks and answers questions about patient reported outcomes. The focus of her lecture is on measuring wellbeing – not only burden of disease.
Thursday, July 1; 11:00-11:45 CEST
Professor Christine Bundy from the UK speaks and answers questions about self-responsibility and self-management – encouraging lasting behaviour change in patients with psoriasis/psoriatic arthritis.
Thursday, July 1; 12:00-12:45 CEST
Professor Dirk Elewaut from Belgium speaks and answers questions on the hot topic of the general impact of the microbiome in chronic, inflammatory disease.
Friday, July 2; 14:00-14:45 CEST
Professor Nehal Mehta from the US speaks and answers questions about vascular inflammation in chronic inflammatory disease.
Friday, July 2; 15:00-15:45 CEST
Professor Mats Lekander from Sweden speaks and answers questions on the pathogenesis of depression in inflammation (chronic and acute).
Saturday, July 3; 14:00-14:45 CEST
Dr. Curdin Conrad from Switzerland speaks and answers questions about the hot topic of psoriasis, psoriatic arthritis, and infectious disease.
Plenary and interactive Q&A sessions
Wednesday, June 30; 10:30-11:10 CEST: Pathogenesis
Speakers include Professor Johan Gudjonsson and Professor Vinod Chandran who focus on the pathogenesis of psoriasis and psoriatic arthritis, respectively.
Wednesday, June 30; 11:10-11:50 CEST: Treatment guidelines
Includes a lecture on treatment guidelines/best practices for psoriasis from Professor Alexander Nast and for psoriatic arthritis from Professor Arthur Kavanaugh.
Wednesday, June 30; 12:10-12:50 CEST: New treatments
Provides updates on new treatments/pipeline from Professor Kristian Reich for psoriasis and Professor Philip Mease for psoriatic arthritis.
Thursday, July 1; 14:00-15:45 CEST: Joint IFPA/GRAPPA session on palmoplantar pustulosis
This collaborative session features patient testimonials followed by lectures from GRAPPA on the particular features, challenges, and recent research on palmoplantar pustulosis.
Friday, July 2; 10:00-11:00 CEST: Comorbidities
This session includes updates from Professor Lone Skov, Dr. Alexis Ogdie-Beatty, and Dr. Josefin Lysell.
Friday, July 2; 11:10-11:50 CEST: Prevention
The different aspects of this complex topic are addressed by Professor Wayne Gulliver, Dr. Frank Behrens, and Dr. Alexander Egeberg.
Friday, July 2; 12:10-13:00 CEST: 20 years of biologics
Speakers include Professor Carle Paul, Professor Kilian Eyerich, Professor Laura Coates, Dr Alexander Egeberg, and Professor Dafna Gladman.
Saturday, July 3; 12:10-13:00 CEST: Topical therapy
Speakers include Professor Lars, Professor Mark, and Professor Wolfgang Weger speaks about measures to improve adherence to topical treatment.
Saturday, July 3; 15:00-15:30 CEST: The consequences of the corona pandemic on the management of psoriasis and psoriatic arthritis
In this session Professor Jo Lambert lectures about whether early registry data are helpful for risk assessment, and Professor Paolo Gisondi talks about SARS-CoV-2 vaccination management in psoriasis and psoriatic arthritis.
Interactive discussion sessions
In an innovative online format featuring live participation from speakers located around the world, these lectures are followed by a live interactive discussion.
Thursday, July 1; 10:00-10:50 CEST
This session’s topic is the role of doctor/patient communication in improving outcomes and wellbeing. It includes lectures from patient expert Silvia Fernandez Barrio, Professor Katy Leung, and Dr. Christian Greis.
Saturday, July 3; 10:00-11:35 CEST
This session’s topic is addressing unmet needs in psoriasis and psoriatic arthritis. The first part of the session session features patient expert Paul Mendoza, Professor Christopher Ritchlin, and Prof. Dr. Ricardo Romiti. In the second part of the session, Professors Ncoza Dlova and Matthias Augustin deliver lectures on addressing stigma.
“Hot topic” session
Saturday, July 3; 11:35-12:00 CEST
This session is designed to approach the pros and cons of a “hit early, hit hard” treatment strategy. Professor Lluis Piug on the pro side and Professor Robert Gniadecki on the con side present the different views and end with a live, interactive discussion where conference attendees participate.
The Complementary Program is primarily directed at allied health professionals, non-specialists, patient leaders, and industry representatives.
Wednesday, June 30; 13:00-14:00 CEST: Global burden of psoriasis/psoriatic arthritis
Speakers include Professor Chris Griffiths, Professor Darren Ashcroft, and Professor Luca Borradori.
Wednesday, June 30; 16:00-17:00 CEST: Psoriatic disease and COVID-19
Speakers include Dr. Satveer Mahil and Professor Catherine Smith from PsoProtect, Professor Peter van de Kerkhof, and Conference President Professor Ulrich Mrowietz.
Thursday, July 1; 13:00-14:00 CEST: Lifestyle, intervention and psoriatic disease
Speakers include Dr. Alan Menter, NCD Alliance’s Lucy Westerman, Professor Luigi Naldi, and Professor Ignacio Dei-Cas.
Thursday, July 1; 16:00-17:00 CEST: Psoriatic disease and its impact on mental health
Speakers include Professor Anthony, Professor Andrea Evers Leiden, Kathleen Gallant, Silvia Fernandez Barrio, and Paul Mendoza.
Friday, July 2; 13:00-14:00 CEST: Rapid access and early intervention
Speakers include Lars Werner from the Danish Psoriasis Association, Professor Jörg Prinz, and IFPA’s Elisa Martini.
Friday, July 2; 16:00-17:00 CEST: Taking global knowledge and implementation at a national level
Speakers include advocate and expert Silvia Fernandez Barrio, Professor April Armstrong, Conference Secretary Barbra Bohannan, Professor Cristina Echeverría, and Dr. Roop Saini.
Saturday, July 3; 13:00-14:00 CEST: International Psoriasis Council – On latest research and updates
Speakers include Professor Lone Skov, Professor Alexander Navarini, and Professor Jo Lambert.
Oral abstract presentations
Wednesday, June 30; 12:50-13:00 CEST
Day 1 features findings from two major abstracts:
Effisayil 1: A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of spesolimab in patients with a generalized pustular psoriasis presented by Professor Mark Lebwohl
Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy and Safety Results From the Phase presented by Professor April Armstrong
Thursday, July 1; 11:50-12:00 CEST
Day 2 features findings from two major abstracts:
Changes in Patient Perceptions of Psoriatic Arthritis From 2012 to 2020: Results From the UPLIFT Survey presented by Dr. Alexis Ogdie
Psoriasis and Psoriatic Arthritis in Transgender Patients on Hormone Therapy: A Retrospective Comparative Cohort Study presented by Julia Gao
Friday, July 2; 11:50-12:00 CEST
Day 3 features findings from two major abstracts:
Identification of serum protein biomarkers at baseline to distinguish radiographic progressors from non-progressors in patients with active Psoriatic Arthritis (PsA) presented by Orla Coleman
Immune checkpoint inhibitors in patients with preexisting psoriasis associated with manageable disease exacerbations and excellent tumor outcomes presented by Briana Halle
Satellite symposia, hosted by sponsors for healthcare personnel only
Wednesday, June 30; 13:10-13:55 CEST
Where do we begin? The key role of the IL-23 pathway in psoriasis and psoriatic arthritis
Wednesday, June 30; 16:15-17:00 CEST
The psoriatic disease spectrum: The data. The clinic. The patient.
Thursday, July 1; 9:00-9:45 CEST
Changing the vision for patients with psoriatic disease
Thursday, July 1; 13:10-13:55 CEST
Commit to clear: empowering a better patient journey
Thursday, July 1; 16:15-17:00 CEST
Advanced Therapeutic Options in PsA: A Multidisciplinary Team Approach
Friday, July 2; 13:10-13:55 CEST
Achieving more for patients with psoriasis: targeting key drivers of disease
Friday, July 2; 16:15-17:00 CEST
One Disease, Two Perspectives: Generalized Pustular Psoriasis Through the Eyes of the Patient and the Dermatologist
IFPA’s 50th Anniversary
Saturday, July 3; 11:50-12:00 CEST
IFPA presents a celebration of the organizations 50th anniversary to honor its history and bestow awards upon individuals who made invaluable contributions over the past 5 decades.
Recorded sessions and poster abstracts are available on-demand until October 3. Don’t forget to stop by the virtual abstract hall to learn about the very latest research on psoriasis and psoriatic arthritis.
About the 6th World Psoriasis & Psoriatic Arthritis Conference 2021
Conference name: 6th World Psoriasis & Psoriatic Arthritis Conference 2021
Theme: “Connected, informed, and united to improve multidisciplinary care for people with psoriasis & psoriatic arthritis”
Dates: June 30 – July 3, 2021
Venue: Virtual Conference broadcast from Stockholm, Sweden
Target group: Dermatologists, rheumatologists and general practitioners and allied health professionals with an interest in psoriasis and psoriatic arthritis
Twitter: @PsoriasisIFPA, #WPPAC21
About IFPA – Global leader in fighting psoriatic disease.
IFPA is a non-profit organization speaking up for 60 million people living with psoriatic disease worldwide. Together, we are determined to build a future where all people living with psoriatic disease enjoy good health and wellbeing, free from stigma and preventable disability and comorbidities.
You can read more about IFPA’s activities on ifpa-pso.com.
Camille Lancelot, IFPA Communications Manager.
Email: email@example.com Telephone: +46 73 961 15 65